MorphoSys

MorphoSys AG is a biopharmaceutical company based in Planegg, Germany, that specializes in the development and commercialization of fully human antibodies for therapeutic applications, particularly targeting cancer and autoimmune diseases. Its lead product candidate, Tafasitamab, is aimed at treating B cell malignancies such as diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company also develops other therapeutic candidates, including Tremfya for various inflammatory conditions, Gantenerumab for Alzheimer's disease, and MOR202 for multiple myeloma. MorphoSys collaborates with notable pharmaceutical partners, including I-Mab Biopharma and Incyte Corporation, to enhance its research and development capabilities. Founded in 1992, the company has established a strong pipeline of innovative drug candidates and continues to engage in strategic alliances to address unmet medical needs in the healthcare sector.

Lucinda Crabtree

CFO

4 past transactions

Constellation Pharmaceuticals

Acquisition in 2021
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

Adivo

Seed Round in 2018
Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

Lanthio Pharma

Acquisition in 2015
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.

Sloning BioTechnology

Acquisition in 2010
Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.